Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

An investigational antisense oligonucleotide, zorevunersen targets the sodium voltage-gated channel alpha subunit 1(SCN1A) gene, which is the primary cause of most Dravet syndrome cases.

Study: Neonatal but not Juvenile Gene Therapy Reduces Seizures and Prolongs Lifespan in SCN1B-Dravet Syndrome Mice ... of the voltage-gated sodium channel (VGSC) in neuronal cell membranes.

Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children ...

A team of researchers has developed a new gene therapy for children with Dravet syndrome -- a rare type of epilepsy in children.

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...